Literature DB >> 6160206

Elevation of substance P-like immunoreactivity in rat central nervous system by protease inhibitors.

G R Hanson, W Lovenberg.   

Abstract

Several substance P-rich areas in rat CNS had increased levels of substance P-like immunoreactivity following the intraventricular injection of the protease inhibitors SQ 20881, SQ 14225, and leupeptin. There were significant differences in response patterns from region to region, possibly on account of an interaction of anatomical, biochemical, or physiological variables. Although the compound SQ 14225 appeared to be the most potent of the inhibitors examined, it had no apparent effect on CNS substance P-like immunoreactivity when administered peripherally.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160206     DOI: 10.1111/j.1471-4159.1980.tb09011.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea.

Authors:  P Devillier; C Advenier; G Drapeau; J Marsac; D Regoli
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

2.  Angiotensin converting enzyme inhibitors potentiate the bronchoconstriction induced by substance P in the guinea-pig.

Authors:  A Subissi; M Guelfi; M Criscuoli
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

3.  The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans.

Authors:  Thomas F Newton; Richard De La Garza; Ken Grasing
Journal:  Psychiatry Res       Date:  2010-05-20       Impact factor: 3.222

4.  Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.

Authors:  Christopher D Verrico; Colin N Haile; Richard De La Garza; Kenneth Grasing; Thomas R Kosten; Thomas F Newton
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.